Compare USLM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | IMNM |
|---|---|---|
| Founded | 1948 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1994 | 2020 |
| Metric | USLM | IMNM |
|---|---|---|
| Price | $113.69 | $21.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $138.00 | $32.80 |
| AVG Volume (30 Days) | 125.7K | ★ 900.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | 23.22 | ★ 51.40 |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $144,435,000.00 | $6,941,000.00 |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $13.76 | $1,127.34 |
| P/E Ratio | $104.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $94.41 | $7.96 |
| 52 Week High | $141.44 | $27.65 |
| Indicator | USLM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 49.13 |
| Support Level | $110.68 | $19.28 |
| Resistance Level | $131.46 | $23.25 |
| Average True Range (ATR) | 3.92 | 1.22 |
| MACD | 1.56 | 0.05 |
| Stochastic Oscillator | 96.24 | 56.39 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.